As the most known GLP-1 brand, Ozempic, going off patent in Canada in 2026, potential generic brands are expected to enter the market, providing affordable options and increasing accessibility
If ongoing studies confirm the early findings surrounding cancer, these therapies may be remembered not only for curbing the obesity epidemic but also reshaping the future of cancer prevention and public health
15, 2022 FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight FDA.gov
These medicines are made under strict controls and are studied in large clinical trials for both safety and effectiveness
J Nanobiotechnol 23 , 576 (2025)
Metabolic Research Use Ideal for GLP-1related studies